Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs.
J Comp Eff Res
; 12(11): e230107, 2023 Nov.
Article
en En
| MEDLINE
| ID: mdl-37655686
ABSTRACT
Aim:
To quantify the economic burden of early-stage non-small-cell lung cancer (NSCLC) among patients with and without adjuvant therapy.Methods:
All-cause and NSCLC-related healthcare resource utilization and medical costs were assessed among patients with resected stage IB-IIIA NSCLC in the SEER-Medicare database (1 January 2011-31 December 2019), from NSCLC diagnosis to death, end of continuous enrollment, or end of data availability (whichever occurred first).Results:
Patients receiving adjuvant therapy had the lowest mean NSCLC-related medical costs (adjuvant [n = 1776] $3738; neoadjuvant [n = 56] $5793; both [n = 47] $4818; surgery alone [n = 3478] $4892, per-person-per-month), driven by lower NSCLC-related hospitalization rates.Conclusion:
Post-surgical management of early-stage NSCLC was associated with high economic burden. Adjuvant therapy was associated with numerically lower medical costs over surgical resection alone.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Carcinoma Pulmonar de Células Pequeñas
/
Neoplasias Pulmonares
Tipo de estudio:
Health_economic_evaluation
Límite:
Aged
/
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
J Comp Eff Res
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos